美國Seracare HIV血清性能盤（HIV Performance Panels）

廣州健侖生物科技有限公司

SeraCare Life Sciences公司主要在美國、歐洲和亞洲提供促進人類和動物診斷和治療學(xué)的探索、開發(fā)和生產(chǎn)的產(chǎn)品和服務(wù)。其業(yè)務(wù)分為兩個部分：診斷和生物制藥產(chǎn)品和生物服務(wù)。診斷和生物制藥產(chǎn)品部門生產(chǎn)和銷售診斷和控制面板產(chǎn)品，用于測試傳染性疾病的臨床實驗室及員工培訓(xùn)和能力測試。生物服務(wù)部門提供生物銀行、來樣加工和測試服務(wù)。

美國SeraCare收購BBI公司，即原BBI血清盤已經(jīng)改名為SeraCare血清盤。

其產(chǎn)品包括有：傳染病陽性質(zhì)控品、疾病標準品、細菌陽性質(zhì)控品、人血清白蛋白、人伽馬球蛋白、牛血清白蛋白、血清盤、人血漿、人血清。

SeraCare的血清盤包括：HIV-1轉(zhuǎn)化盤、HIV性能盤、HBV轉(zhuǎn)化盤、HBV性能盤、HCV轉(zhuǎn)化盤、HCV性能盤、弓形蟲性能盤、線性盤和質(zhì)控盤等等。

我司還提供其它進口或國產(chǎn)試劑盒：登革熱、瘧疾、流感、A鏈球菌、合胞病毒、腮病毒、乙腦、寨卡、黃熱病、基孔肯雅熱、克錐蟲病、違禁品濫用、肺炎球菌、軍團菌、化妝品檢測、食品安全檢測等試劑盒以及日本生研細菌分型診斷血清、德國SiFin診斷血清、丹麥SSI診斷血清等產(chǎn)品。

歡迎咨詢

歡迎咨詢2042552662

美國Seracare HIV血清性能盤（HIV Performance Panels）

美國Seracare 

想了解更多的產(chǎn)品及服務(wù)請掃描下方二維碼：

【公司名稱】 廣州健侖生物科技有限公司

【市 場 部】    楊永漢

【】 

【騰訊Q Q】 2042552662

【公司地址】 廣州清華科技園創(chuàng)新基地番禺石樓鎮(zhèn)創(chuàng)啟路63號二期2幢101-103室

綜上所述，該研究發(fā)現(xiàn)能量水平能夠調(diào)節(jié)全反式維甲酸合成，這種調(diào)節(jié)作用主要是通過胰島素和Foxo1影響Rdh表達實現(xiàn)的。這一研究成果對研究全反式維甲酸與胰島素信號通路的相互作用在II型糖尿病等胰島素相關(guān)疾病中的作用具有一定意義。
近日，A * STAR研究員確定了一種磷酸蛋白在促進健康細胞自毀和卵巢癌進展中的作用。磷酸蛋白PTP4A3已知在癌細胞中過表達，其可以作為生物標志物，用于疾病預(yù)后。
為了生長和擴散，癌細胞積極“劫持”一些人體的自然細胞過程(如自噬)。自噬對于維持健康的細胞是必要的。
自噬是通過細胞器即自噬體來完成的，自噬體的任務(wù)是“拆除”細胞，運輸無用的細胞物質(zhì)用于回收并組成新的膜和蛋白質(zhì)。自噬過程中自噬體會經(jīng)歷成熟過程，這使得他們能夠履行其有效的作用。
通過進行一系列的實驗，科學(xué)家們已經(jīng)發(fā)現(xiàn)在自噬過程中，PTP4A3過表達和自噬體成熟加速發(fā)生之間的。利用表達PTP4A3的卵巢癌細胞開展實驗，結(jié)果發(fā)現(xiàn)PTP4A3利用自噬途徑以促進癌細胞生長。
研究人員還發(fā)現(xiàn)，PTP4A3積聚在自噬體，加快其成熟過程。這反過來“鼓勵”健康細胞的被破壞，并允許癌癥“冒頭”。
通過對卵巢癌患者數(shù)據(jù)進行分析，研究小組發(fā)現(xiàn)高水平的PTP4A3連同自噬基因與人類卵巢癌患者預(yù)后差顯著相關(guān)。這意味著，PTP4A3水平可能在未來充當(dāng)一個有用的生物標志物。此外，研究人員發(fā)現(xiàn)，抑制自噬能減少PTP4A3驅(qū)動癌細胞生長。

In summary, the study found that energy levels can modulate all-trans retinoic acid synthesis, and this regulation is mainly achieved through insulin and Foxo1 affecting Rdh expression. This research result has certain significance for studying the role of the interaction between all-trans retinoic acid and insulin signaling pathway in insulin-related diseases such as type II diabetes.
Recently, the A*STAR researcher determined the role of a phosphoprotein in promoting the self-destruction of healthy cells and the progression of ovarian cancer. The phosphoprotein PTP4A3 is known to be overexpressed in cancer cells, which can serve as a biomarker for disease prognosis.
In order to grow and spread, cancer cells actively "hijack" some of the body's natural cellular processes (such as autophagy). Autophagy is necessary to maintain healthy cells.
Autophagy is accomplished through organelles called autophagosomes. The task of autophagosomes is to "dismantle" cells and transport useless cellular material to recover and form new membranes and proteins. Autophagic processes undergo a maturation process during autophagy, which allows them to perform their effective role.
Through a series of experiments, scientists have discovered a link between PTP4A3 overexpression and accelerated autophagic maturation during autophagy. Using an ovarian cancer cell expressing PTP4A3 to perform the experiment, it was found that PTP4A3 utilizes an autophagy pathway to promote cancer cell growth.
The researchers also found that PTP4A3 accumulates in the autophagosome and accelerates its maturation process. This in turn "encourages" the destruction of healthy cells and allows cancer to "rise its head".
By analyzing the data of patients with ovarian cancer, the team found that high levels of PTP4A3 along with autophagy genes are significantly associated with poor prognosis in human ovarian cancer patients. This means that PTP4A3 levels may act as a useful biomarker in the future. In addition, the researchers found that inhibiting autophagy can reduce the growth of PTP4A3-driven cancer cells.